Botulinum toxin: Examining duration of effect in facial aesthetic applications

American Journal of Clinical Dermatology

Volumn 11, Issue 3, 2010, Pages 183-199

  Flynn, Timothy Corcoran ^a,b  

^a Cary Skin Center   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Botulinum toxin; Botulinum toxin A; Botulinum toxin B; Facial wrinkles; Glabellar lines; Therapeutic use; Treatment

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; COSMETIC; NEURONOX; NEUROTOXIN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; FACE; HUMAN; LOW LEVEL LASER THERAPY; PATIENT SATISFACTION; PHOTOTHERAPY; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WRINKLE;

BOTULINUM TOXINS; CLINICAL TRIALS AS TOPIC; COSMETIC TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTHETICS; FACE; HUMANS; NEUROTOXINS; SKIN AGING; TIME FACTORS;

EID: 77950663627     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11530110-000000000-00000     Document Type: Review

References (65)

1. American Society forAesthetic Plastic Surgery. Cosmetic surgery national data bank: 2007 statistics [online]. Available from URL: http://www.surgery.org/ download/2007stats.pdf [Accessed 2008 Apr 9]
2. MacPherson S. Self-esteem and cosmetic enhancement. Plast Surg Nurs 2005; 25 (1): 5-20
3. Finn JC, Cox SE, Earl ML. Social implications of hyperfunctional facial lines. Dermatol Surg 2003; 29 (5): 450-455
4. Cox SE, Finn JC. Social implications of hyperdynamic facial lines and patient satisfaction outcomes. Int Ophthalmol Clin 2005; 45 (3): 13-24
5. Aoki KR, Ranoux D, Wissel J. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol 2006; 13 Suppl. 4: 10-19
6. De Boulle KLV. Botulinum neurotoxin type A in facial aesthetics. Expert Opin Pharmacother 2007; 8 (8): 1059-1072
7. Botoxcosmetic [package insert]. Irvine (CA): Allergan, Inc., 2005
8. Dysport Clostridium botulinum type A toxin-haemagglutinin complex: summary of product characteristics [online]. Available from URL: http://emc. medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=870 [Accessed 2007 Apr 13]
9. Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 2001; 8 Suppl. 5: 21-29
10. Aoki KR. Future aspects of botulinum neurotoxins. J Neural Transm 2008; 115 (4): 567-573
11. Aoki KR, Satorius A, Ardila C, et al. Pharmacology of BOTOX, Dysport, Myobloc and BTX-A in animal models of efficacy and safety [abstract]. International Conference on Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins; 2005 Jun 23-25; Denver (CO)
12. Dolly JO, Aoki KR. The structure and mode of action of different botulinum toxins. Eur J Neurol 2006; 13 Suppl. 4: 1-9
13. Eleopra R, Tugnoli V, Quatrale R, et al. Different types of botulinum toxin in humans. Mov Disord 2004; 19 Suppl. 8: S53-9
14. Rosales RL, Bigalke H, Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol 2006; 13 Suppl. 1: 2-10
15. Setler P. The biochemistry of botulinum toxin type B. Neurology 2000; 55 (12 Suppl. 5): S22-8
16. Gordon MF, Barron R. Effectiveness of repeated treatment with botulinum toxin type A across different conditions. South Med J 2006; 99 (8): 853-861
17. Carruthers JDA, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 1992; 18 (1): 17-21
18. Hankins CL, Strimling R, Rogers GS. Botulinum A toxin for glabellar wrinkles: dose and response. Dermatol Surg 1998; 24: 1181-1183
19. Carruthers A, Carruthers J, Lowe NJ, et al., for the BOTOX- Glabellar Lines I & II Study Groups. One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. J Clin Res 2004; 7: 1-20
20. Carruthers A, Carruthers J, Said S. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg 2005; 31 (4): 414-422
21. Carruthers A, Carruthers J. Prospective, double-blind, randomized, parallelgroup, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatol Surg 2005; 31 (10): 1297-1303
22. Stotland MA, Kowalski JW, Ray BB. Patient-reported benefit and satisfaction with botulinum toxin type A treatment of moderate to severe glabellar rhytides: results from a prospective open-label study. Plast Reconstr Surg 2007; 120 (5): 1386-1393
23. Carruthers A, Carruthers J, Cohen J. Dilution volume of botulinum toxin type A for the treatment of glabellar rhytides: does it matter? Dermatol Surg 2007; 33 (1 Spec. No.): S97-104
24. Lowe P, Patnaik R, Lowe N. Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. J Am Acad Dermatol 2006; 55 (6): 975-980
25. Lowe NJ, Yamauchi PS, Lask GP, et al. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing. J Cosmet Laser Ther 2002; 4 (1): 15-18
26. Ascher B, Zakine B, Kestemont P, et al. A multicenter, randomized, doubleblind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 2004; 51 (2): 223-233
27. Ascher B, Zakine B, Kestemont P, et al. Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesth Surg J 2005; 25: 365-375
28. Monheit G, Carruthers A, Brandt F, et al. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose.Dermatol Surg 2007; 33 (1 Spec. No.): S51-9 (Pubitemid 46051400)
29. Rzany B, Ascher B, Fratila A, et al., for the GLADYS Study Group. Efficacy and safety of 3- and 5-injection patterns (30 and 50U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol 2006; 142 (3): 320-326
30. Alster TS, Lupton JR. Botulinum toxin type B for dynamic glabellar rhytides refractory to botulinum toxin type A. Dermatol Surg 2003; 29 (5): 516-518
31. Sadick NS. Botulinum toxin type B for glabellar wrinkles: a prospective openlabel response study. Dermatol Surg 2002; 28 (9): 817-821
32. Sadick NS. Prospective open-label study of botulinum toxin type B (Myobloc-) at doses of 2,400 and 3,000U for the treatment of glabellar wrinkles. Dermatol Surg 2003; 29 (5): 501-507
33. Carruthers A, Carruthers J, Flynn TC, et al. Dose-finding, safety, and tolerability study of botulinum toxin type B for the treatment of hyperfunctional glabellar lines. Dermatol Surg 2007; 33 (1 Spec. No.): S60-8 (Pubitemid 46051401)
34. Levy JL, Servant JJ, Jouve E. Botulinum toxin A: a 9-month clinical and 3D in vivo profilometric crow's feet wrinkle formation study. JCosmet Laser Ther 2004; 6 (1): 16-20
35. Lowe NJ, Ascher B, Heckmann M, et al., on behalf of the Botox Facial Aesthetics Study Team. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. Dermatol Surg 2005; 31 (3): 257-262
36. Carruthers A, Bogle M, Carruthers JD, et al.Arandomized, evaluator-blinded, two-center study of the safety and effect of volume on the diffusion and efficacy of botulinum toxin type A in the treatment of lateral orbital rhytides. Dermatol Surg 2007; 33 (5): 567-571
37. Matarasso SL. Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. Dermatol Surg 2003; 29 (1): 7-13
38. Baumann L, Slezinger A, Vujevich J, et al. A double-blinded, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc- (botulinum toxin type B)-purified neurotoxin complex for the treatment of crow's feet: a double-blinded, placebo-controlled trial. Dermatol Surg 2003; 29 (5): 508-515
39. Lew H, Yun YS, Lee SY, et al. Effect of botulinum toxin A on facial wrinkle lines in Koreans. Ophthalmologica 2002; 216 (1): 50-54
40. Carruthers A, Carruthers J, Cohen J. A prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in female subjects with horizontal forehead rhytides. Dermatol Surg 2003; 29 (5): 461-467
41. Levy JL, Pons F, Jouve E.Management of the ageing eyebrow and forehead: an objective dose-response study with botulinum toxin. J Eur Acad Dermatol Venereol 2006; 20 (6): 711-716
42. Ahn KY, Park MY, Park DH, et al. Botulinum toxin A for the treatment of facial hyperkinetic wrinkle lines in Koreans. Plast Reconstr Surg 2000; 105: 778-784
43. Ramirez AL, Reeck J, Maas CS. Botulinum toxin type B (Myobloc-) in the management of hyperkinetic facial lines. Otolaryngol Head Neck Surg 2002; 126 (5): 459-467
44. Rzany B, Dill-Müller D, Grablowitz D, et al. Repeated botulinum toxin A injections for the treatment of lines in the upper face: a retrospective study of 4,103 treatments in 945 patients. Dermatol Surg 2007; 33 (1 Spec. No.): S18-25
45. Ahn MS, Catten M, Maas CS. Temporal brow lift using botulinum toxin A. Plast Reconstr Surg 2003; 112 (5 Suppl.): 98S-104S
46. Spó sito MMM. New indications for botulinum toxin type A in treating facial wrinkles of the mouth and neck. Aesth Plast Surg 2002; 26 (2): 89-98
47. Beer K, Yohn M, Closter J. A double-blinded, placebo-controlled study of BOTOX for the treatment of subjects with chin rhytids. J Drugs Dermatol 2005; 4 (4): 417-422
48. Carruthers J, Carruthers A. A prospective, randomized, parallel group study analyzing the effect of BTX-A (BOTOX) and nonanimal sourced hyaluronic acid (NASHA, Restylane) in combination compared with NASHA (Restylane ) alone in severe glabellar rhytides in adult female subjects: treatment of severe glabellar rhytides with a hyaluronic acid derivative compared with the derivative and BTX-A. Dermatol Surg 2003; 29 (8): 802-809
49. Carruthers J, Carruthers A. The effect of full-face broadband light treatments alone and in combination with bilateral crow's feet botulinum toxin type A chemodenervation. Dermatol Surg 2004; 30 (3): 355-366
50. Zimbler MS, Holds JB, Kokoska MS, et al. Effect of botulinum toxin pretreatment on laser resurfacing results: a prospective, randomized, blinded trial. Arch Facial Plast Surg 2001; 3 (3): 165-169
51. Patel MP, Talmor M, Nolan WB. Botox and collagen for glabellar furrows: advantages of combination therapy. Ann Plast Surg 2004; 52 (5): 442-447
52. Guyuron B, Huddleston SW. Aesthetic indications for botulinum toxin injection. Plast Reconstr Surg 1994; 93 (5): 913-918
53. Cox SE, Finn JC, Stetler L, et al. Development of the Facial Lines Treatment Satisfaction Questionnaire and initial results for botulinum toxin type A-treated patients. Dermatol Surg 2003; 29 (5): 444-449
54. Flynn TC, Clark RE. Botulinum toxin type B (Myobloc-) versus botulinum toxin type A (BOTOX-) frontalis study: rate of onset and radius of diffusion. Dermatol Surg 2003; 29 (5): 519-522
55. Lowe NJ, Lask G, Yamauchi P, et al. Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet. J Am Acad Dermatol 2002; 47 (6): 834-840
56. Simonetta Moreau M, Cauhepe C, Magues JP, et al. A double-blind, randomized, comparative study of Dysport- vs. BOTOX- in primary palmar hyperhidrosis. Br J Dermatol 2003; 149 (5): 1041-1045
57. Jost WH, Kohl A, Brinkmann S, et al. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers. J Neural Transm 2005; 112 (7): 905-913
58. Nussgens Z, Roggenkamper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol 1997; 235 (4): 197-199
59. Bihari K. Safety, effectiveness, and duration of effect of BOTOX- after switching from Dysport- for blepharospasm, cervical dystonia, and hemifacial spasm. Curr Med Res Opin 2005; 21 (3): 433-438
60. Odergren T, Hjaltason H, Kaakkola S, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and BOTOX in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998; 64 (1): 6-12
61. Sampaio C, Ferreira JJ, Simoes F, et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A- Dysport and BOTOX- assuming a ratio of 4:1. Mov Disord 1997; 12: 1013-1018
62. Ranoux D, Gury C, Fondarai J, et al. Respective potencies of BOTOX and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002; 72 (4): 459-462
63. Chapman MA, Barron R, Tanis DC, et al. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. Clin Ther 2007; 29 (7): 1325-1337
64. Trindade De Almeida AR, Marques E, De Almeida J, et al. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg 2007; 33 (1 Spec. No.): S37-43
65. Lowe PL, Patnaik R, Lowe NJ. A comparison of two botulinum type A toxin preparations for the treatment of glabellar lines: double-blind, randomized, pilot study. Dermatol Surg 2005; 31 (12): 1651-1654